Compare CACC & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CACC | TFX |
|---|---|---|
| Founded | 1972 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.6B |
| IPO Year | 1996 | 1994 |
| Metric | CACC | TFX |
|---|---|---|
| Price | $464.11 | $110.42 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 8 |
| Target Price | ★ $470.00 | $140.29 |
| AVG Volume (30 Days) | 233.2K | ★ 823.1K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | ★ 1.25% |
| EPS Growth | ★ 83.00 | N/A |
| EPS | ★ 36.38 | N/A |
| Revenue | ★ $2,317,200,000.00 | $1,992,713,000.00 |
| Revenue This Year | $91.73 | $46.78 |
| Revenue Next Year | $3.58 | $3.86 |
| P/E Ratio | $12.84 | ★ N/A |
| Revenue Growth | ★ 7.16 | N/A |
| 52 Week Low | $401.90 | $100.18 |
| 52 Week High | $549.75 | $143.32 |
| Indicator | CACC | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 46.69 |
| Support Level | $450.83 | $109.60 |
| Resistance Level | $489.50 | $125.12 |
| Average True Range (ATR) | 22.33 | 4.03 |
| MACD | -5.46 | -1.05 |
| Stochastic Oscillator | 28.55 | 20.32 |
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.